3
Participants
Start Date
September 5, 2018
Primary Completion Date
February 29, 2020
Study Completion Date
October 9, 2020
NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).
Cyclophosphamide
a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.
Fludarabine
a chemotherapy agent used for lymphodepletion prior to NYCE T cells.
NY-ESO-1 expression testing
Testing to determine if NY-ESO-1 is expressed on tumor tissue.
University of Pennsylvania, Philadelphia
Collaborators (1)
Parker Institute for Cancer Immunotherapy
OTHER
Gilead Sciences
INDUSTRY
University of Pennsylvania
OTHER